BTG develops and commercialises acute care and specialty pharmaceutical products for the treatment of diseases with high unmet medical need. We have established US commercial operations and an acute care sales force to promote and sell our specialty pharmaceutical products, CroFab® (crotalidae polyvalent immune fab (ovine)) and DigiFab® (digoxin immune fab (ovine)). We recently launched Voraxaze® (glucarpidase), following US regulatory approval. In 2011, we formed a US commercialisation partnership with Wellstat Therapeutics Corporation to exclusively market Wellstat’s investigational antidote, uridine triacetate, following FDA approval. In May 2012 we extended this partnership and acquired EU named patient supply rights to uridine triacetate with the option to acquire the EU commercial rights upon EU approval.
Our Business Development strategy is focused on forming strategic partnerships that complement our expertise in developing and marketing acute care products. We are interested in exploring global and regional partnerships for products within the following areas:
- Marketed products that can be sold through our dedicated hospital-focused sales force
- Late-stage development programmes that target disease areas treated by specialists with high unmet medical needs
- Medical toxicology and oncology antidotes that complement our commercial and development-stage antidote franchise
For Business Development opportunities within Specialty Pharmaceuticals, please send your enquiries to:
Richard Mason, Head of Business Development
BTG International Ltd
We have a proud history of partnering and a number of partnered programmes in late stage development, which we believe may have significant commercial potential.